Endothelial Progenitor Cells in Diabetic Vasculopathy by Meiliana, Anna & Wijaya, Andi
4The Indonesian Biomedical Journal, Vol.1, No.2, August 2009, p.4-23 Print ISSN: 2085-3297, Online ISSN: 2355-9179
Endothelial Progenitor Cells in Diabetic Vasculopathy
Anna Meiliana1,2* and Andi Wijaya1,2* 
R E V I E W  A R T I C L E
1Post Graduate Program in Clinical Biochemistry,  Hasanuddin 
University, Makassar
2Prodia Clinical Laboratory, Jakarta
B
ACKGROUND: The discovery of endothelial 
progenitor cell (EPC) a decade ago by Asahara 
et al has refuted the previous belief that 
vasculogenesis only occurs during embryogenesis. 
The reduced circulating concentration of EPCs is a 
surrogate marker of endothelial function and has 
been implicated in the pathogenesis of many vascular 
diseases.
CONTENT: Diabetes is linked to impaired vascular 
function, including alterations in both endothelial 
cells and EPCs. A number of studies have shown 
that individuals with diabetes have decreased level 
of circulating EPCs and that the severity of disease 
is inversely proportional to EPC levels. In vitro, 
hyperglycemia increases the rate of EPC senescence 
and the angiogenic function of EPCs from patients 
with either type 1 or type 2 diabetes is impaired such 
that they are poorly proliferative and fail to incorporate 
into forming vessel-like structures.
Given the comprehensive role of EPC alterations in 
diabetes complications, modulation of the levels and/
or function of EPCs may be considered a potential 
therapeutic strategy.
SUMMARY: The available data demonstrating that 
decrease or dysfunction of EPCs may have a prominent 
role in the pathogenesis of all diabetes complications.
Further approaches, such as EPC administration, may 
represent novel treatments for diabetic vasculopathy 
Abstract
in the future. To date, many barriers remain to such 
a therapeutic approach. Firstly, there is no speciﬁc 
marker for EPC at present. Secondly, techniques of 
EPC isolation are not standardized, preventing direct 
comparison between various studies. The long-term 
effects of transplanted EPCs are currently unknown.
Introduction
*Address correspondence to this author at: Prodia Clinical 
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EPCs can promote postnatal vasculogenesis by homing 
to, differentiating, proliferating and incorporating 
into new vessels. EPCs may play a role in this 
process by physically incorporating or may inﬂuence 
neighbouring cells in a paracrine fashion. These 
normal roles of EPCs may explain why these cells 
have been implicated in the pathogenesis of many 
vascular disease states such as ischaemia, restenosis 
and pulmonary hypertension (1-6). EPC number and 
function can be affected by various cardiovascular 
risk factors such as cigarette smoking, hypertension 
and hyperlipidaemia (7–9). In fact, Hill et al. have 
demonstrated that EPC number may be a surrogate 
biologic marker for vascular function and cumulative 
cardiovascular risk in healthy men (10). Schmidt-Lucke 
et al. and Werner et al. later showed that the number 
of circulating EPCs can predict the occurrence of 
cardiovascular events and death from cardiovascular 
causes and may help to identify patients at increased 
cardiovascular risk (11,12). EPC dysfunction has also 
been observed in the high cardiovascular risk state of 
diabetes mellitus (DM).
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Diabetic  Complications
The impaired neovascularization found in the 
diabetic setting may be explained by the inability of 
diabetic EPCs to respond to stromal-derived factor-1 
(SDF-1), which plays a crucial role in EPC homing (13). 
Dysfunctional EPCs in the diabetic setting are also 
associated with impaired re-endothelialization (14). 
Furthermore, EPC mobilization was also impaired 
after ischaemic reperfusion injury in a streptozotocin 
induced diabetic mouse model, a ﬁnding that was 
associated with altered SDF-1 and VEGF release as well 
as impaired hypoxia inducible factor-1a upregulation 
(15). These in vivo animal studies demonstrated that 
diabetes is associated with impaired EPC mobilization, 
differentiation and ability to form tubules.
The administration of both autologous and 
heterologous unfractionated BM cells, which contain 
EPCs, has produced dramatic improvement in 
neovascularization in various ischaemic states (16-26). 
However, the results of autologous EPC transplantation 
in the diabetic setting may not be as promising. As 
discussed above, in patients with DM, EPC numbers 
are lower and their function is impaired.
Diabetes complications represent a huge burden 
for patients and health services. The ﬁght against 
each single complication has led to signiﬁcant 
improvements in diabetes care, especially for 
microvascular complications, yet macroangiopathy 
remains a major source of morbidity and mortality. A 
common approach for the prevention and treatment of 
diabetes complications relies on the understanding of 
their complex pathophysiology (27).
While it was originally thought that a single patient 
tends to develop the cluster of micro- or macrovascular 
complications, recent prospective studies show that 
typical markers of microvascular dysfunction, such as 
microalbuminuria or retinal vascular abnormalities, 
are associated with an increased risk of macrovascular 
events (28,29). These and other data suggest that there 
must be a unifying pathogenetic model underlying 
diabetes complications. To date, the most credited 
and supported model proposes that oxidative stress 
originating from mitochondria activates all subcellular 
damage pathways (30). However, subsequent events 
diverge for each complication, and there is not a 
supracellular unifying hypothesis. The discovery that 
a subset of circulating immature cells contributes to 
vascular homeostasis has been a major achievement in 
many ﬁelds of basic science.
Endothelial progenitor cells (EPCs) are circulating 
immature cells that contribute to vascular homeostasis 
and compensatory angiogenesis. During the last 
decade, data have become available indicating that 
alterations in EPCs may have an important causative 
role in the development and progression of virtually 
all diabetes complications (27).
Endothelial  Progenitor Cells  (EPCs)
EPCs were discovered in 1997 as circulating cells with 
the ability to differentiate into mature endothelium 
and take part in neoangiogenesis (1). EPCs share 
markers of hematopoietic (CD34 and CD133) and 
endothelial (KDR, CD31, and vWf) lineages (31), are 
derived from bone marrow, and can be mobilized to 
the peripheral circulation in response to many stimuli 
(32). Tissue ischemia, through the release of growth 
factors and cytokines, mobilizes EPCs, which, once 
in the peripheral circulation, speciﬁcally home on the 
ischemic sites to stimulate compensatory angiogenesis 
(33). Moreover, EPCs constitute a circulating pool of 
cells able to form a cellular patch at sites of endothelial 
injury, thus contributing directly to the homeostasis 
and repair of the endothelial layer. Taken together, 
these observations suggest that EPCs have a major 
role in cardiovascular biology; in fact, the extent of 
the circulating EPC pool is now considered a mirror 
of cardiovascular health. Virtually all risk factors for 
atherosclerosis have been associated with decrease 
and/or dysfunction of circulating EPCs (34), while 
an expanded EPC pool is associated with a decreased 
cardiovascular mortality (11).
According to the initial discovery, EPCs or CEPCs 
(Circulating bone marrow – derived endothelial 
progenitor cells) were deﬁned as cells positive for 
both  hematopoietic stem cell markers such as CD34 
and an endothelial marker protein as VEGFR2. 
Because CD34 is not exclusively expressed on 
hematopoietic stem cells but, albeit at a lower level, 
also on mature endothelial cells, further studies used 
the more immature hematopoietic stem cell marker 
CD133+ and demonstrated that puriﬁed CD133+ 
cells can differentiate to  endothelial cells in vitro (35). 
CD133, also known as prominin or AC133, is a highly 
conserved antigen with unknown biological activity, 
which is expressed on hematopoietic stem cells but is 
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absent on mature endothelial cells and monocytic cells 
(36) Thus, CD133+VEGFR2+ cells more likely reﬂect 
immature progenitor cells, whereas CD34+VEGFR2+ 
may also represent shedded cells of the vessel wall. At 
present, it is unclear whether CD133 only represents a 
surface marker or has a functional activity involved in 
regulation of neovascularization. Overall, controversy 
exists with respect to the identiﬁcation and the origin 
of endothelial progenitor cells, which are isolated from 
peripheral blood mononuclear cells by cultivation 
in medium favoring endothelial differentiation. In 
peripheral blood mononuclear cells, several possible 
sources for endothelial cells may exist: (1) the rare 
number of hematopoietic stem cells, (2) myeloid cells, 
which may differentiate to endothelial cells under the 
cultivation selection pressure, (3) other circulating 
progenitor cells (eg, “side population” cells), and (4) 
circulating mature endothelial cells, which are shed off 
the vessel wall (37)  and adhere to the culture dishes 
(38).
A combination of CD34, kinase insert domain-
containing receptor (KDR) and CD133 are commonly 
used to deﬁne EPCs at present. The use of ﬂuorescence-
activated cell sorter (FACS) analysis to deﬁne EPCs 
appears to be the most optimal approach but may be 
technically challenging and the best combination of the 
‘true’ markers for EPCs is currently unknown (39).
The study of EPC biology consists of two related 
aspects: quantitative evaluation of the EPC pool 
and functional assessment. Circulating EPCs can 
be quantiﬁed directly ex vivo using ﬂow cytometry, 
which is considered the gold standard for this purpose 
(40); typical surface antigens to identify EPCs are 
CD34, CD133, and KDR. Functional characteristics are 
explored in vitro using standardized protocols (38). 
Proliferation refers to the ability of EPCs to expand 
and form colonies in culture: EPCs should proliferate 
in response to growth factors released locally after 
vascular damage or tissue ischemia. Adhesion is a 
further step required for both reendothelization and 
angiogenesis; it is assessed as the ability of EPCs to 
adhere to a monolayer of mature endothelium in 
culture. Migration of EPCs through the extracellular 
matrix is crucial for the growth of new vessels and 
is generally assessed in vitro as the ability to invade 
the lower side of a Boyden-like chamber. Finally, after 
EPCs have adhered to the vessel wall, migrated into 
the interstitium, and expanded locally, they should 
spatially organize to form vascular structures; this 
property can be assessed in vitro as a tube formation 
assay in which EPCs are seeded with human umbilical 
vein endothelial cells on a gel of extracellular matrix 
proteins.
Two types of EPC had different morphology, 
proliferation rates, and survival behaviors. They also 
had different gene expression proﬁles, leading to 
different function in vitro. Despite such differences 
in gene expression and in vitro function, they equally 
contributed to neovasculogenesis in vivo in that early 
EPC secreted angiogenic cytokines, whereas late EPC 
supplied a sufﬁcient number of endothelial cells (41).
Late EPC was different from early EPC in the 
expression of VE-cadherin, Flt-1, KDR, and CD45. 
Late EPC produced more nitric oxide, incorporated 
more readily into human umbilical vein endothelial 
cells monolayer, and formed capillary tube better than 
early EPC. Early EPC secreted angiogenic cytokines 
(vascular endothelial growth factor, interleukin 8) 
more so than late EPC during culture in vitro. Both 
types of EPC showed comparable in vivo vasculogenic 
capacity (41).
Distinct origins of the different types of EPCs exist 
that have different functions in neovascularization. 
Mixed transplantation of these cells results in 
synergistic neovascularization through cytokines and 
MMPs (42).
EPCs in Neovascularization
Improvement of neovascularization is a therapeutic 
option to rescue tissue from critical ischemia (43). 
The ﬁnding that bone marrow–derived cells can 
home to sites of ischemia and express endothelial 
marker proteins has challenged the use of isolated 
hematopoietic stem cells or EPCs for therapeutic 
vasculogenesis.
However, the number of incorporated cells with an 
endothelial phenotype into ischemic tissues is generally 
quite low. How can such a small number of cells 
increase neovascularization? A possible explanation 
might be that the efﬁciency of neovascularization may 
not solely be attributable to the incorporation of EPCs 
in newly formed vessels, but may also be inﬂuenced 
by the release of proangiogenic factors in a paracrine 
manner (38).
Thus, EPCs may act similar to monocytes/
macrophages, which can increase arteriogenesis by 
providing cytokines and growth factors. Indeed, EPCs 
cultivated from different sources showed a marked 
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expression of growth factors such as VEGF, HGF, and 
IGF-1. Moreover, adherent monocytic cells, which were 
cultivated under similar conditions, but do not express 
endothelial marker proteins, also release VEGF, HGF, 
and G-CSF (44). The release of growth factors in turn 
may inﬂuence the classical process of angiogenesis, 
namely the proliferation and migration as well as 
survival of mature endothelial cells (45). However, 
EPCs additionally incorporated into the newly formed 
vessel structures and showed endothelial marker 
protein expression in vivo.
EPCs in Endothelial  Regeneration
In the past, the regeneration of injured endothelium 
has been attributed to the migration and proliferation 
of neighboring endothelial cells. More recent studies, 
however, indicate that additional repair mechanisms 
may exist to replace denuded or injured arteries.
Bone marrow transplantation experiments 
revealed that bone marrow–derived cells can contribute 
to reendothelialization of grafts and denuded 
arteries (46-48). However, in a model of transplant 
arteriosclerosis, bone marrow–derived cells appear 
to contribute only to a minor extent to endothelial 
regeneration by circulating cells (49). These data 
again indicate that there might be at least two distinct 
populations of circulating cells that principally are 
capable to contribute to reendothelialization, namely 
mobilized cells from bone marrow and non-bone 
marrow–derived cells. The latter ones may arise from 
circulating progenitor cells released by non-bone 
marrow sources (eg, tissue resident stem cells) or 
represent vessel wall–derived endothelial cells (49, 46-
48). 
A rapid regeneration of the endothelial monolayer 
may prevent restenosis development by endothelial 
synthesis of antiproliferative mediators such as 
nitric oxide. Indeed, enhanced incorporation of 
-galactosidase–positive, bone marrow–derived cells 
was associated with an accelerated reendothelialization 
and reduction of restenosis (46,47). Similar results 
were reported by Griese et al, who demonstrated 
that infused peripheral blood monocyte–derived EPC 
home to bioprosthetic grafts and to balloon-injured 
 a htiw detaicossa gnieb rettal eht ,seiretra ditorac
signiﬁcant reduction in neointima deposition (50). 
Likewise, infusion of bone marrow–derived CD34-/
CD14+  mononuclear cells, which are not representing 
the population of the “classical hemangioblast,” 
contributed to endothelial regeneration (51). The 
regenerated endothelium was functionally active 
as shown by the release of NO (51), which is 
supposed to be one of the major vasculoprotective 
mechanisms. Consistently, neointima development 
was signiﬁcantly reduced after cell infusion (51). 
Whereas the regeneration of the endothelium by EPCs 
protects lesion formation, bone marrow–derived 
stem/progenitor cells may also contribute to plaque 
Figure 1. Role of EPCs in vascular biology. Reprinted by permission from Wolter Kluwer Health, Circ.Res, Copyright (2004).
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angiogenesis, thereby potentially facilitating plaque 
instability (52). However, in a recent study, no inﬂuence 
of bone marrow cell infusion on plaque composition 
was detected in nonischemic mice (53). An increase 
in plaque size was only detected in the presence of 
ischemia, suggesting that ischemia-induced release of 
growth factors predominantly accounts for this effect 
(53). 
Overall, these studies implicate that regardless 
of the origin of circulating endothelial progenitor 
cells, this pool of circulating endothelial cells may 
exert an important function as an endogenous repair 
mechanism to maintain the integrity of the endothelial 
monolayer by replacing denuded parts of the artery 
(Figure 1). One can speculate that these cells may 
also regenerate the low grade endothelial damage 
by ongoing induction of endothelial cell apoptosis 
induced by risk factors for coronary artery disease 
(54).
Moreover, various risk factors for coronary artery 
disease, such as diabetes, hypercholesterolemia, 
hypertension, and smoking, affect the number and 
functional activity of EPCs in healthy volunteers (10) 
and in patients with coronary artery disease (55).
In addition, factors that reduce cardiovascular 
risk such as statins (56,46,47,57) or exercise (58) 
elevate EPC levels, which contribute to enhanced 
endothelial repair. The balance of  atheroprotective 
and proatherosclerotic factors, thus, may inﬂuence 
EPC levels and subsequently reendothelialization 
capacity.
The release of EPCs from the bone marrow is 
regulated by a variety of growth factors, enzymes, 
ligands, and surface receptors. Activation of 
matrix metalloproteinase-9, which promotes the 
transformation of membrane-bound Kit ligand to 
a soluble Kit ligand and the subsequent move of 
cKit-positive stem and progenitor cells, including 
a common hematopoietic and angioblast precursor 
(hemangioblast), to the vascular zone of the bone 
marrow microenvironment, are initial steps in this 
complex process (59). The signals, which initiate the 
diversion of the hemangioblast to either hematopoietic 
precursor cells or EPCs, are largely unknown at present 
but may include angiogenic growth factors from the 
periphery.
To date, no clear deﬁnition exists as to when 
an endothelial progenitor cell turns into a mature, 
fully differentiated endothelial cell in vivo. One 
possibility could be the loss of CD133 and a parallel 
or subsequent expression of von Willebrand factor in 
conjunction with the appearance of other endothelial 
characteristics. The starting point of this differentiation 
process may by the migration of EPCs from the bone 
marrow to the systemic circulation. After homing, ie, 
after adhesion and insertion into the monolayer of 
surrounding mature vascular ECs, this process may 
be completed (60).
Recruitment and incorporation of EPCs requires 
a coordinated sequence of multistep adhesive and 
signaling events including chemoattraction, adhesion, 
and transmigration, and ﬁnally the differentiation to 
endothelial cells (Figure 2) (38).
The local bone marrow microenvironment, the 
 ,stsalborbﬁ fo gnitsisnoc ehcin llec mets dellac-os
osteoblasts, and endothelial cells, governs the 
maintenance and mobilization of bone marrow stem 
cells (61,62,63). Mechanistically, cytokines inducing 
mobilization interfere with the interactions between 
stem cells and bone marrow stromal cells, which 
allow stem cells to disengage the bone marrow, and to 
pass through the sinusoidal endothelium to enter the 
blood stream. Stem cell mobilization is mediated by 
proteinases such as elastase, cathepsin G, and matrix 
metalloproteinases (MMPs) (64). A cytokine clinically 
used for the mobilization of CD34+ cells in patients 
is G-CSF, which releases the proteinases elastase and 
cathepsin G from neutrophils. These proteinases 
induce cleavage of adhesive bonds on stromal cells, 
which interact with integrins on hematopoietic stem 
cells (65). Moreover, these proteinases cleave the 
cytokine SDF-1, which is released by stromal cells 
and its receptor CXCR4 on stem and progenitor cells 
(66). Stem cell mobilization as a result of high levels 
of circulating SDF-1 appears to reverse the SDF-1 
gradient across the bone marrow barrier, forcing 
CXCR-4+ cells to exit the bone marrow (67). However, 
VEGF, SDF-1, and placental growth factor (PlGF)-
induced stem cell mobilization was shown to rely on 
MMP-9 (59,68). When PlGF is administered in the early 
phase of bone marrow recovery, it is chemoattractive 
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Figure 2.  Mechanism of EPC homing and differentiation. Reprinted by permission from Wolters Kluwer Health, Circ. Res, Copyright (2004).
for VEGF-receptor-1+ stem cells, whereas in later 
stages PlGF functions are mediated by MMP-9 (68). 
Thus, increasing the local concentration of MMP-9 
in the bone marrow cleaves membrane bound Kit 
ligand (mKitL) and, ﬁnally, releases soluble Kit ligand 
(KitL; also known as stem cell factor) (59). After all, 
this process transfers endothelial and hematopoietic 
progenitor cells from the quiescent to the proliferative 
niche. However, the question of whether G-CSF–
induced stem cell mobilization depends on MMP-9 
is still a matter of debate (59,69,70). This controversy 
might be explained by the fact that MMP-9 plays a 
pivotal role in growth factor-induced hematopoietic 
progenitor mobilization in wild-type animals, whereas 
compensatory upregulation of enzymes with a similar 
activity proﬁle to MMP-9 might mask the impact of 
MMP-9 deﬁciency in the knockout model. As discussed, 
eNOS is essential to maintain adequate progenitor cell 
mobilization in response to distinct stimuli, including 
VEGF, statins, exercise, and estrogen, in the regulation 
of stem and progenitor cell mobilization (58,62,71,72). 
The defective mobilization was caused by the lack of 
eNOS (Nos3) provided by the bone marrow stromal 
microenvironment.
Therefore, eNOS deﬁciency in the bone marrow 
microenvironment impaired the mobilization of 
stem and progenitor cells from the bone marrow. In 
contrast, intravenous injection of stem and progenitor 
cells circumvented the defective mobilization from the 
bone marrow and improved the neovascularization 
after induction of hind limb ischemia. Therefore, 
eNOS-derived NO is a physiological regulator of stem 
and progenitor cell mobilization in the bone marrow 
stromal microenvironment.
Given that patients with coronary artery disease 
showed a diminished NO bioavailability in peripheral 
endothelial cells, one may speculate that this also 
translates into the bone marrow.  EPC numbers are 
lower in patients with coronary artery disease or 
diabetes (55,74) and are correlated with NO-dependent 
vasorelaxation measured in the forearm (10).
Hypoxia, caused by an imbalance between oxygen 
supply and consumption, stimulates vasculogenesis 
in embryonic and adult tissue (75-79). Similarly, 
hypoxia, and the subsequent alteration of HIF-1, can 
induce VEGF and SDF-1, which stimulates migration 
of endothelial precursors during vasculogenesis 
(78,80). Therefore, it can be suggested that hypoxia 
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in embryonic and adult target tissue leads to an 
expression of chemotactic factors inducing migration 
of angioblasts and EPCs toward the region to be 
vascularized by vasculogenesis.
SDF-1 gene expression is regulated by the 
transcription factor hypoxia-inducible factor-1  in 
endothelial cells, resulting in selective in vivo 
expression of SDF-1 in ischemic tissue in direct 
proportion to reduced oxygen tension. HIF-1-induced 
SDF-1 expression increases the adhesion, migration 
and homing of circulating CXCR4-positive progenitor 
cells to ischemic tissue.
These data show that the recruitment of CXCR4-
positive progenitor cells to regenerating tissues is 
mediated by hypoxic gradients via HIF-1-induced 
expression of SDF-1 (80).
In brief, the directed migration of angioblasts is 
regulated by a combination of different soluble and 
interaction molecules that build overlapping attractive 
and repulsive gradients of soluble factors forming the 
migratory route for the endothelial precursor cells. It 
can be suggested that the correct positioning of the 
endothelial cells after they start to migrate toward the 
target tissue is dependent on a ﬁne balance of signals. 
Soluble factor from regions that should be vascularized 
diffuse to the endothelial precursors, attract them and 
keep them in their migratory phenotype state until 
they reach their ﬁnal position (81).
Vascular endothelial growth factor caused 
the phosphorylation of AMPK, acetyl-coenzymeA 
(CoA) carboxylase (ACC), and eNOS in human cord 
blood-derived EPCs. The expression of EC markers, 
including VE-cadherin and intercellular adhesion 
molecule1 (ICAM-1), was also increased but blocked 
by Compound C, an AMPK inhibitor. AICAR, an 
AMPK agonist, increased the phosphorylation of ACC 
and eNOS and the expression of EC markers in a time- 
and dose-dependent manner, which reinforces the 
positive effect of AMPK on EPC differentiation.
The activation of eNOS by AMPK during EPC 
differentiation provides a novel mechanism for 
the pleiotropic effects of statins in beneﬁting the 
cardiovascular system (82).
There is accumulating evidence that platelets 
mediate the effect of hematopoietic cytokines to recruit 
bone marrow–derived cells to the vasculogenic niche. 
Thrombopoietic cytokines thrombopoietin (TPO) 
and stem cell factor (SCF) are signiﬁcantly elevated 
shortly after ischemic tissue injury, and transgenic 
mice deﬁcient in TPO or the TPO receptor (c-MPL) 
demonstrate signiﬁcantly impaired hind – limb 
revascularization and inhibited angiogenic tumor 
growth (83). 
Aggregation of activated platelets was necessary 
for the recruitment of bone marrow–derived c-Kit+ 
ScaI+ Lin- progenitor cells and CD34+ cells to sites of 
endothelial disruption (84). Hematopoietic cells were 
unable to adhere directly to the exposed extracellular 
matrix, but were
tethered to platelet surface P-selectin via P-selectin 
glycoprotein ligand (PSGL)-1 binding. Platelet release 
of SDF-1 provided an ongoing retention signal for 
bone marrow–derived cells at these sites (84). The 
mechanism by which platelets release SDF-1, VEGF 
and other growth factors in a site-speciﬁc fashion is 
likely to involve glycoprotein (GP) IIb– dependent 
platelet aggregation (84), inward receptor signaling, 
and MMP-9–mediated SDF-1 release (83). In addition 
to platelet-derived SDF-1, exposed smooth muscle 
cells also produce SDF-1 after arterial injury, and 
platelet activation via CXCR4 signaling leads to 
P-selection upregulation, further promoting arrest of 
bone marrow–derived cells to activated endothelium 
(85).
Taken together, these data suggest that aggregation 
and activation of platelets at sites of exposed 
subendothelium and vasculogenesis play a major role 
in the recruitment, differentiation, and incorporation 
of bone marrow–derived progenitor cells.
These insights have profound clinical implications; 
inhibition of platelet-deployed growth factors or their 
receptors may be an effective strategy to block tumor 
growth, whereas activation of these pathways may 
be used to accelerate revascularization and tissue 
regeneration (86).
Endothelial progenitor cells (EPCs) and 
hematopoietic progenitor cells are recruited to ischemic 
regions, improving neovascularization. 1 and 2 
integrins play a crucial role for progenitor cell homing 
to ischemic tissues. Integrin activity is regulated by 
chemokines and their respective G protein– coupled 
receptors. The phosphatidylinositol-3-kinase catalytic 
subunit  (PI3K ) is the PI3K isoform that selectively 
transduces signals from G protein–coupled receptors. 
A pharmacological PI3K  inhibitor signiﬁcantly 
reduced chemokine – induced chemotaxis and stromal 
cell–derived factor (SDF)1 -induced transmigration 
of human EPCs. Moreover, the PI3K  inhibitor 
signiﬁcantly reduced SDF1 -induced adhesion of 
EPCs to intercellular adhesion molecule-1 and human 
umbilical vein endothelial cell monolayers (87,88).
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Adverse effects of EPC mobilization have 
been described as contribution of EPCs to tumor 
neovascularization in some tumor models (89). 
Moreover, circulating progenitor cells have been 
implicated in the neovascularization of arteriosclerotic 
lesions of allografts and in further atherosclerotic plaque 
progression in an ischemic setting (52,53). However, 
transfusion of EPCs enhanced re-endothelialization 
and reduced neointima formation after vascular injury 
(47). One may speculate that the endothelial repair 
capacity might override the potential harmful effects 
of plaque neovascularization. Thus, future studies 
have to determine the overall inﬂuence of EPC levels 
on atherosclerotic disease progression and prognosis 
(32).
Cardiovascular Risk Factors and EPCs
Small clinical studies have shown that the number 
of circulating EPCs inversely correlates with risk 
factors for atherosclerosis (10,55). Circulating CD34/
KDR-positive progenitor cells are reduced to ~50% 
in patients with CAD compared with control groups. 
In addition, EPCs isolated from patients with CAD 
displayed an impaired migratory response, which was 
inversely correlated with the number of cardiovascular 
risk factors (55).
In patients with arterial hypertension, systolic 
blood pressure negatively correlates with the number 
of circulating CD133+ and CD34+/KDR+ EPCs, 
whereas the clonogenic potential (number of colony 
forming units–ECs) is not impaired by arterial 
hypertension (55). Experimental data demonstrate 
that angiotensin II, a potent mediator of detrimental 
effects in arterial hypertension, can accelerate the 
onset of EPC senescence by gp91 phox – mediated 
increase in oxidative stress, leading to an impaired 
proliferation activity of EPCs. Angiotensin II–induced 
EPC senescence was inhibited by treatment with the 
angiotensin II type 1 receptor blocker valsartan (90).
Recent studies have underlined the detrimental 
effects of types 1 and 2 diabetes on EPC function (74,91). 
Tepper et al demonstrated that in type 2 diabetes 
proliferation capacity of EPCs was reduced, adhesion 
capacity on activated human ECs was impaired. 
Hypercholesterolemia was associated with 
reduced EPC numbers in 20 age-matched patients 
with hypercholesterolemia (8). Proliferative capacity, 
migratory activity, and in vitro vasculogenesis were 
negatively inﬂuenced by hypercholesterolemia. The 
underlying mechanisms are probably an increased 
rate of EPC senescence/apoptosis, as demonstrated 
after incubation of EPCs with oxidized LDL (92).
A role for HDL in promoting the repair of injured 
endothelium by stimulating the recruitment of 
endothelial progenitor cells (EPCs) into the endothelial 
layer (93).
Smoking has been identiﬁed as an important 
risk factor for reduced EPC numbers in one of the 
ﬁrst studies on cardiovascular risk factors by Vasa et 
al (55). However, Wang et al recently demonstrated 
that the role of nicotine is more complex than 
initially expected (94). In an experimental study, they 
demonstrated that low concentrations of nicotine (10-
8-10-12 mol/L) increased EPC number and activity, 
whereas higher (toxic) concentrations (>10-6 mol/L) 
were associated with cytotoxicity. In humans, Kondo 
et al demonstrated that chronic smokers (n=15) exhibit 
reduced EPC levels that can be restored after smoking 
cessation within 4 weeks (9).
In humans, a signiﬁcant increase in progenitor 
cell numbers was observed in patients who resumed a 
standardized physical activity during a rehabilitation 
program (58), in patients with CAD (95), and in healthy 
individuals exercising for ≥30 minutes (96).
CRP, at concentrations known to predict 
adverse vascular outcomes, directly inhibits EPC 
differentiation, survival, and function, key components 
of angiogenesis and the response to chronic ischemia. 
This occurs in part via an effect of CRP to reduce EPC 
eNOS expression. The PPAR  agonist rosiglitazone 
inhibits the negative effects of CRP on EPC biology. 
The ability of CRP to inhibit EPC differentiation and 
survival may represent an important mechanism that 
further links inﬂammation to cardiovascular disease 
(97).
To contribute to tissue repair, EPCs, and stem cells 
in general, have to be equipped with antioxidative 
defense systems to survive in necrotic and ischemic 
tissues. Interestingly, a high resistance to oxidative 
stress has been considered a characteristic feature of 
stem cells (98,99).
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He et al demonstrate that human EPCs possess 
a unique property to withstand oxidative injury and 
that elevated expression of manganese superoxide 
dismutase (MnSOD, a mitochondria-located SOD) is 
a critical intrinsic mechanism protecting EPCs against 
oxidative stress (100).
The ﬁnding that GPx-1 expression is essential for 
EPC functions may also have clinical implications, 
given that patients with chronic heart failure (101) and 
with type 2 diabetes (102) showed a downregulation 
of GPx-1. This in turn may contribute to the reduced 
EPC numbers and functions in patients with 
coronary artery disease and severe heart failure 
(55,103). However, other antioxidative enzymes such 
as superoxide dismutases and catalases are also 
downregulated in these patients (101,102). Thus, it 
seems mandatory to understand the speciﬁc role of the 
various antioxidative enzymes for EPC functions. In 
the future, a speciﬁc interference with the expression 
and activity of antioxidative enzymes in progenitor 
cells from patients might be a therapeutic strategy to 
improve their regenerative potential (104).
Schroeter et al (105) have now demonstrated 
that infusion of leptin-stimulated human EPCs 
reduces neointima formation and enhanced 
reendothelialization through upregulation of v 5- 
and 4-integrin–dependent adhesion to platelets in 
ferric chloride–induced vascular injury. With this 
elegant approach, the effect of leptin on EPC-mediated 
endothelial recovery can be readily discerned from 
leptin-enhanced thrombosis. This not only extends the 
mechanisms by which platelet-derived chemokines, 
P-selectin, and 2 integrins can support the arrest of 
EPCs and CD34+ progenitor cells at sites of arterial 
injury (85,106) but also adds a new dimension to the 
functional proﬁle of leptin.
PPAR-  activation with agonist (GW501516 or 
L-165041) increased the proliferation of human EPCs 
and protected them from hypoxia-induced apoptosis. 
In addition, PPAR-  activation enhanced EPC 
functions, such as transendothelial migration, and 
tube formation. These actions by PPAR-  activation 
in EPCs were dependent on the phosphatidylinositol 
3-kinase/Akt pathway (107).
What are the mechanisms by which risk factors 
mediate their negative effect on progenitor cells? 
It appears that the signaling pathways mediating 
progenitor cell impairment are similar to the previously 
identiﬁed regulators of endothelial cell function and 
atherosclerosis and include a dysregulation of nitric 
oxide (NO) and reactive oxygen species (ROS). A 
diabetic environment or high glucose exposure in 
vitro is associated with reduced nitric oxide (NO) 
bioavailability in cultured EPCs, and plasma levels of 
endogenous NO – synthase inhibitors (asymmetrical 
dimethyl-L-arginine) are associated with clinically 
reduced EPC numbers (108). In experimental studies, 
endothelial NO synthase (eNOS)-derived NO was 
shown to be essential for basal, VEGF-, and SDF-1– 
induced migration of EPCs or bone marrow–derived 
progenitor cells, and eNOS-/- progenitor cells showed 
a reduced homing capacity in ischemia models in vivo 
(109,110). The underlying mechanisms mediating the 
NO effects, eg, on chemokines or integrin expression or 
signaling, need to be further deﬁned. Despite various 
studies supporting an important role of eNOS for 
progenitor cell mobilization and function (58,71,109), 
under certain conditions, eNOS uncoupling may lead 
to an increased ROS production. To what extent the 
redox balance in stem cells (as opposed to cultured 
EPCs or crude bone marrow homogenates used in the 
study(111) favors such uncoupling processes is unclear 
and deserves further studies.
In healthy individuals and patients with coronary 
artery disease, age is associated with a reduced 
number and function of cultured EPCs, circulating 
CD34+KDR+ cells, or CD133+ cells and of granulocyte 
macrophage colony forming units (GM-CFUs) in the 
bone marrow (11,55,112).
On a molecular level aging is linked to a reduction 
of telomere length. The proliferative history of a cell 
is written on telomeres: telomere erosion reﬂects the 
number of past divisions experienced by a cell and 
its proliferative potential (113).  In addition, telomere 
erosion may contribute to telomere shortening. 
When long telomeres protect chromosomal ends, 
cells can undergo repeated cell divisions. Conversely, 
telomere shortening beyond a critical length leads to 
genomic instability, DNA damage, p53 activation, and 
ultimately cell cycle arrest (114).
In summary, experimental and clinical studies 
demonstrated that aging interferes with progenitor cell 
functions. To what extent the dysfunction is exclusively 
related to age-associated telomere shortening and 
intrinsic cell dysfunction (eg, senescence) or might also 
involve age-dependent changes in paracrine activities 
remains to be deﬁned (115).
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EPCs Alteration in Diabetes
Both cytometric and culture methods have extensively 
demonstrated that type 1 and type 2 diabetic patients 
have less circulating EPCs than matched healthy 
subjects. Moreover, diabetic EPCs display functional 
impairment, such as reduced proliferation, adhesion, 
migration, and incorporation, into tubular structures 
(74,91,116). The mechanisms underlying EPC reduction 
in diabetes include weak bone marrow mobilization, 
decreased proliferation, and shortened survival in 
peripheral blood (127).
Poor collateral formation in diabetes may be 
attributed to weaker bone marrow stimulation from 
the ischemic tissue. Fadini et al (27) have recently 
conﬁrmed this hypothesis, showing that bone marrow 
mobilization of EPCs after ischemia-reperfusion injury 
is defective in diabetic rats. Inability to mobilize EPCs 
was associated with downregulation of HIF-1  and 
weakened release of marrow – stimulating factors, such 
 tneicﬁfusni ot gnidael yletamitlu ,1-FDS dna FGEV sa
compensatory angiogenesis (15). Another study has 
shown that progenitor cell mobilization restored 
blood ﬂow in diabetic mice (117). It is conceivable 
that HIF-1  deregulation in diabetes depends on an 
overproduction of reactive oxygen species (ROS).
Although molecular mechanisms that regulate 
EPC release in peripheral blood are complex and not 
fully understood, a role for the phosphatidylinositol 
(PI) 3-kinase/protein kinase-B and endothelial nitric 
oxide (NO) synthase pathways has been shown 
(72,118). As diabetes is characterized by altered 
activation of PI 3-kinase/Akt pathways and by 
reduced NO bioavailability (119), dysfunction of 
these subcellular pathways may be involved in the 
defective mobilization of EPCs from bone marrow. 
Hyperglycemia may be the common feature that 
affects survival and function of EPCs because similar 
alterations have been demonstrated in both type 1 
and type 2 diabetes. In vivo, hyperglycemia induces 
oxidative stress by increasing the production of ROS 
and alters leukocyte and endothelial function (30).
Recently, Krankel et al. (120) have convincingly 
demonstrated that high glucose impairs proliferation, 
survival, and function of cultured EPCs, with 
concomitant-decreased NO production and matrix 
metalloproteinase-9 activity. Furthermore, activation 
of mitogen-activated protein kinases has been revealed 
as a potential mechanism of EPC dysfunction induced 
by high glucose (121). A deﬁnite demonstration is 
that correction of hyperglycemia by insulin therapy 
(15,122) can indeed restore the normal EPC pool.
Fadini et al (27) shown that patients with 
the metabolic syndrome have decreased levels of 
CD34+KDR+ EPCs compared with patients without 
the syndrome (116). Circulating CD34+ cells are 
synergically decreased by clustering components of 
the metabolic syndrome, and their levels negatively 
correlate with the homeostasis model assessment 
value, a measure of insulin resistance (123). In fact, 
insulin resistance, the typical hallmark of metabolic 
syndrome, is characterized by a defective activation of 
the PI 3-kinase/Akt pathway and decreased endothelial 
NO synthase activity, which are considered essential 
for EPC mobilization and function. Oxidative stress 
plays a crucial role in the pathogenesis of diabetes 
complications (30), as well as in the entire atherogenic 
process. Therefore, stress-induced apoptosis may be 
one mechanism of EPC reduction in diabetes. The 
literature provides ample evidence that EPCs might 
decrease because of increased apoptosis and that EPCs 
are stress sensitive (124).
In summary, reduction in circulating EPCs 
in diabetic patients may recognize at least three 
pathophysiological explanations: impaired bone 
marrow mobilization, defective proliferation, and 
enhanced apoptosis. Remarkably, in accordance 
with Brownlee’s unifying hypothesis (30), oxidative 
stress appears as a major determinant of all of these 
mechanisms. Interestingly, two very recent studies 
have demonstrated that the natural transketolase 
activator, benfotiamine, which is theoretically able to 
prevent the subcellular damage pathways triggered 
by oxidative stress, restored EPC-mediated healing of 
ischemic diabetic limbs in mice (125) and prevented 
hyperglycemia – mediated EPC dysfunction via 
modulation of the Akt pathway (126).
EPCs and the Diabetic  Paradox
High blood glucose is an extremely detrimental factor 
for the retinal microvasculature. Hyperglycemic 
damage results in increased permeability, blood 
and serum leakage to the extravascular space, and 
progressive decline in retinal blood ﬂow. Retinal 
ischemia and release of angiogenic factors stimulate the 
proliferation of microvessels, leading to proliferative 
retinopathy. Recently, intriguing novelties have been 
added to this pathogenetic model. In animals, bone 
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marrow–derived cells are mobilized and recruited 
at sites of retinal neovascularization in response to 
VEGF and SDF-1 (127,128). Therefore, not only local 
endothelial cells, but also EPCs may be involved in the 
development of proliferative retinopathy. This seems 
counterintuitive, as diabetes complications that may 
affect the same patient, such as diabetic retinopathy 
and PAD, can have opposing EPC alterations, the 
one being associated with increased and the other 
with decreased EPC levels. Parallely, a single diabetic 
patient can presentat the same time with complications 
of excessive angiogenesis (proliferative diabetic 
retinopathy) and of poor angiogenesis (symptomatic 
PAD) (27). 
An unexplained paradox puzzles diabetologists: 
diabetic patients must face both poor vessel  growth in 
ischemic heart and limbs and increased angiogenesis in 
retinal complications (129,130). Endothelial progenitor 
cells (EPCs) are marrow-derived cells involved in 
adult neovascularization and endothelial homeostasis 
(1,131). It has been postulated that low EPCs in 
peripheral blood may have a role in cardiovascular 
disease, and we have demonstrated that EPCs are 
reduced in macrovascular diabetes complications 
(10,116). On the other hand, an excess of EPCs may be 
involved in pathologic neoangiogenesis of cancer and 
proliferative retinopathy (132,133). Therefore, diabetes 
complications may be associated with both decreased 
and increased EPCs. Recently, novel therapeutic 
approaches have been directed to enrich the EPC 
pool in ischemic diseases and to block EPC function 
in proliferative diseases (128,134). These approaches 
in diabetic subjects require cautious evaluation of the 
implications carried by the paradox and new studies 
to unravel its causes (135,136).
Fadini et al (141) show that CD34+ cells and 
CD34+KDR+ cells are differentially altered in the 
presence of DR and PAD. These two common diabetes 
complications exhibit a very different behavior in 
terms of angiogenic response to ischemia, and this 
contrast has been termed “diabetic paradox.” Many 
growth factors have been proposed to have a role in 
this phenomenon (137-139), all of which are potent 
stimuli for progenitor cell mobilization and homing 
to ischemic tissues (32). Indeed, recent data indicate 
that marrow-derived cells are involved in retinal 
neovascularization and that DR+ patients have 
increased levels of circulating progenitors (133,140). 
Conversely, macrovascular complications are 
characterized by reduced angiogenesis and exhausted 
EPC levels (116). This ﬁndings suggest that enhanced 
endothelial differentiation of circulating progenitors 
characterize DR, as shown by the high CD34+KDR+ 
proportion and the enhanced efﬁciency of EPC culture 
in contrast with the poor endothelial differentiation of 
PAD patients (141).
Therefore, the differential regulation of circulating 
progenitors, possibly in association with different 
oxygen gradients and local accumulation of growth 
factors, may explain why peripheral ischemia cannot 
stimulate angiogenesis as retinal ischemia does. Going 
deeper into the systemic events accompanying retinal 
vascular proliferation may provide novel therapeutic 
targets against peripheral ischemic complications. The 
notion that EPCs may be involved in retinal vascular 
proliferation should induce caution when trying to 
expand the EPC pool to ameliorate the cardiovascular 
proﬁle. For instance, erythropoietin itself is an 
angiogenic factor that may worsen proliferative 
diabetic retinopathy (142).
Therapeutic  Potential  of  EPC in Neovascularization
In vivo models of limb ischemia and myocardial 
infarction supported a direct role for bone marrow–
derived cells in neovascularization, concluding that 
these cells differentiate into smooth muscle and 
endothelial cells that incorporate into neovessels 
(143-146). However, more recently, other groups 
have contested these ﬁndings and suggest that bone 
marrow–derived progenitor cells act primarily via 
paracrine mechanisms, secreting chemokines such 
as angiopoietin-1 and vascular endothelial growth 
factor (VEGF) at sites of vascular injury to enhance 
local angiogenic function (147-149). It remains to 
be determined whether these discrepancies are 
attributable to differences in study design, such as 
the choice of bone marrow cell populations selected 
and the ischemic models used. Based on the current 
evidence, however, it appears that EPCs may make 
both direct contributions to neovascularization as 
well as indirectly promote the angiogenic function 
of local endothelial cells via secretion of angiogenic 
factors(150).
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A number of factors have been shown to enhance 
EPC function either at the site of mobilization from the 
bone marrow and/or at sites of homing to damaged 
blood vessels. Age-associated decreases in a wide 
range of factors, includingVEGF and PDGF signaling 
and circulating estrogen levels have been suggested in 
animal models to be important factors in the decrease 
in EPC mobilization from the bone marrow, cardiac 
homing, and regeneration (151-153).
Clinical trials in patients with coronary artery 
disease or limb ischemia showed improvement after 
treatment with plasmid DNA encoding VEGF165 
(154-157); thus VEGF may prove to be a feasible and 
successful therapy for vascular injury.
PDGF acts to promote the angiogenic activity of 
local vascular cells after myocardial infarction as well 
as to recruit bone marrow cells that differentiate into 
both endothelial cells and cardiomyocytes (158,159). 
Intramyocardial treatment with PDGF therefore 
appears to enhance the interactions between bone 
marrow and cardiac stem cell niches and provides 
functional beneﬁt to the injured heart. Additionally, 
studies recently demonstrated that PDGF pathways are 
essential for maintaining the cardiomyogenic potential 
of Oct3/4+ bone marrow cells that is decreased with 
age (160).
Tenascin-C, which we have shown to be a 
downstream mediator of PDGF signaling in the cardiac 
vasculature, is associated with sites of EPC recruitment 
in the heart and is also important for bone marrow 
cell–mediated mechanisms of cardiac angiogenesis 
(161). This protein is downregulated in the aging bone 
marrow and may also be depleted in the aging heart 
(161). Thus mechanisms that restore tenascin-C may 
have multiple actions that promote cardiovascular 
repair mechanisms, including CSC-mediated cardiac 
regeneration.
Another factor acting both in the cardiac and bone 
marrow stem cell niches is stromal cell–derived factor 
(SDF)-1. In the bone marrow, SDF-1 is among a number 
of proteins, including VEGF and placental growth 
factor, that induce matrix metalloproteinase (MMP)-9, 
leading to the translocation of stem cells to the vascular 
zone of the bone marrow before mobilization (59). 
SDF-1 has also been shown to promote bone marrow 
cell proliferation and angiogenesis (162).
Other factors that regulate EPC function include 
the hematopoietic growth factor granulocyte 
macrophage–colony stimulating factor, which 
increases the number of circulating EPCs in vivo, 
while enhancing differentiation of EPCs in vitro (33). 
Similarly G-CSF also has stimulated EPC mobilization 
in clinical trials, but these EPCs display functional 
impairment of migratory properties in vitro.
Pharmacologically, the class of factors known as 
the statins, or 3-hydroxy-3-methyl glutaryl coenzyme 
A reductase inhibitors, has also been shown to 
enhance EPCmediated angiogenesis in models 
of ischemic tissue injury. In vivo, statin treatment 
increases the numbers of circulating EPCs and 
enhances both neovascularization in corneal assays 
and reendothelialization of injured vessels, promoting 
incorporation of labeled bone marrow–derived cells 
into these vessels (46,56,163). Mechanistically, statin 
treatment in vitro appears to inhibit EPC senescence, 
via induction of telomere repeat binding factor-2, which 
inhibits induction of the DNA damage checkpoint-
kinase 2 (164). Simvastatin activates the serine–
threonine kinase Akt in endothelial cells, promoting 
endothelial cell survival and migration (165). Akt also 
acts downstream of VEGF and may therefore represent 
a key regulator of VEGF-mediated neovasculogenesis 
(166). Thus, these data suggest that statin therapy may 
constitute an important approach in the development 
of strategies to improve EPC survival and function 
and to improve cardiac repair pathways in the aging 
population. Indeed, the TOPCARE-AMI clinical trial 
demonstrated that the treatment of ex vivo cultured 
blood-derived progenitor cells with atorvastatin 
was found to be safe and potentially effective for the 
enhancement of cardiac regeneration (167).
EPC Transplantation in Diabetes
Accelerated atherosclerosis is probably the most 
devastating among diabetes complications. The 
atherogenetic process in diabetic subjects is similar 
to that observed in their nondiabetic counterparts. 
However, diabetic vasculopathy is characterized by 
high prevalence, early development, bilaterality, rapid 
progression, and typical involvement of multiple distal 
sites. The severity of macrovascular complications in 
diabetes has been attributed to a profoundly impaired 
collateralization of vascular ischemic beds (168), which 
is insufﬁcient to overcome the loss of blood ﬂow, and 
leads to critical limb ischemia that often requires 
amputation. The mechanisms that hinder ischemia-
induced neovascularization in diabetes had remained 
elusive until the discovery of EPCs. In animal models 
of diabetic vasculopathy, defective collateralization 
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was counteracted by administration of EPCs from 
control animals. Conversely, diabetic EPCs were not 
able to stimulate vascularization, even becoming 
antiangiogenic (169,170). Additionally, EPCs appeared 
important for vascularization and healing of diabetic 
wounds (171).
Patients with diabetes and PAD had a further 
signiﬁcant decrease in circulating EPC levels, especially 
in the presence of ischemic foot lesions. Remarkably, 
EPC levels strongly correlated with the anklebrachial 
index, the most objective diagnostic and prognostic 
test for lower extremity arterial disease (116).
Lower-limb atherosclerosis: higher degrees 
of carotid stenosis, as well as worse stages of leg 
claudication and ischemic lesions, were associated 
with lower levels of EPCs, suggesting that EPC 
count may be considered a valuable marker of 
atherosclerotic involvement. Indeed, cytometric 
techniques, which allow EPC count, arewidely used 
for routine laboratory testing, and the determination 
of EPCs is sufﬁciently reproducible to be used in the 
clinical practice (11,40,123). 
In the case that EPCs are deﬁned as CD34+KDR+ 
cells. The clinical usefulness would stand in 
that EPCs not only mirror vascular function and 
atherosclerotic burden but also reﬂect the endogenous 
vasculoregenerative potential. Importantly, there are 
data suggesting that measuring EPCs would provide 
additional information over the classical risk factor 
analysis; in one study (11), CD34+KDR+ EPC count 
predicted cardiovascular events independently of 
risk factors and hard indexes, such as left ventricular 
ejection fraction. Moreover, EPCs isolated from diabetic 
patients with PAD exhibited impaired proliferation 
and adhesion to mature endothelium (172). We suggest 
that impaired collateralization leading to the clinical 
manifestations and complications of atherosclerosis 
in diabetes may be attributable to decreased and 
dysfunctional EPCs.
Huang et al. (23) have transplanted bone marrow–
mobilized cells, as an EPC enriched fraction, into 
critically ischemic limbs of diabetic patients. Compared 
with standard therapy, cell therapy improved 
angiographic scores and ankle-brachial index values 
and reduced relevant end points, such as ulcer size 
and need for limb amputation (27). Recently, Körbling 
et al. were able to isolate a large quantity of clinically 
graded EPC from healthy volunteers by leukaparesis 
after G-CSF stimulation (173). This method may offer 
promise as a means of improving the efﬁcacy of EPC 
transplantation for therapeutic neovascularization in 
the diabetic setting. However, previous data, while 
suggesting that G-CSF or granulocyte–macrophage 
colony – stimulating factor (GM-CSF) administration 
did increase EPC mobilization, the therapeutic effect in 
patients with coronary artery disease was conﬂicting 
(174,175).
Figure 3. Approaches to improve efﬁcacy of EPC transplantation in diabetic setting. 
(Reprinted by permission from Wiley-Blackwell Publisher, Diabetes Obesity and Metabolism, Copyright 2007).
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More recent data have shown that transplantation 
of G-CSF-mobilized EPCs for the treatment of critical 
limb ischaemia in patients with DM is safe and effective 
(23). Nevertheless, further studies are required to 
ensure the safety of this approach. EPC number can 
also be increased by augmenting the differentiation 
ability of MNC by co-administration of growth 
factors with unfractionated BM-MNC. For instance, 
co-administration of placental growth factor and BM-
MNC into a diabetic hindlimb mouse model augments 
EPC differentiation from diabetic BM-MNCsin vitro 
(176).
Improved neovascularization can also be achieved 
in a diabetic hindlimb ischaemic mouse model by 
inhibition of NADPH oxidase–derived reactive 
oxidative species overproduction (177). Silencing of 
apoptotic gene expressionsuch as p53 renders EPCs 
derived from patients with T2DM more resistant 
to oxidative stress. This method also reduces EPC 
senescence and improves their ability to differentiate 
and form tubules in vitro (178). Lastly, administration 
of benfotiamine has been recently shown to increase 
EPC number and reverse EPC dysfunction in patients 
with DM (125,126).  
Other growth factors such as VEGF, transforming 
growth factor- 1, angiopoetin-1, SDF-1, constitutive 
telomerase reverse transcriptase, hepatocyte growth 
factor, PDGF-B, basic ﬁbroblast growth factor and 
Diabetes complications represent a huge burden for 
patients and health services. A common approach 
for the prevention and treatment of diabetes 
complications relies on the understanding of their 
complex pathophysiology.
During the last decade, data have become available 
indicating that alteration in EPCs may have an 
important causative role in all diabetes complications. 
New approaches such as EPC administration may 
represent novel treatments for diabetic vasculopathy 
in the future. To date, many barriers remain to such 
a therapeutic approach, hopefully in the near future 
these problems can be resolved.
Conclusion
medications such as erythropoietin, oestrogen, 
phosphodiesterase-5 inhibitor, puerarin and Ginkgo 
biloba have been shown to augment EPC number 
and function in a non-diabetic settings (179). These 
factors, however, have not been studied in the setting 
of diabetes but may be beneﬁcial for therapeutic 
neovascularization in DM. The approaches to improve 
efﬁcacy of EPC transplantation in diabetic setting is 
summarized in ﬁgure 3 (39).
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